SCHEMBL2916296

SCHEMBL2916296

Cc1c(NCCO)ccc2cnc(Nc3cc(N)c4cn[nH]c4c3)nc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTK P33981 1/20 0.35
CDK2 P24941 2/20 0.34
EGFR P00533 1/20 0.34
CCNA2 P20248 1/20 0.34
EPHB4 P54760 4/20 0.34
SYK P43405 5/20 0.32
PDGFRB P09619 2/20 0.32
PDGFRA P16234 2/20 0.32
CDC7 O00311 1/20 0.32
IDO1 P14902 2/20 0.32
TDO2 P48775 2/20 0.32
METAP2 P50579 1/20 0.32
DAPK3 O43293 1/20 0.32
PRKD3 O94806 1/20 0.32
MAP4K4 O95819 1/20 0.32
PAK4 O96013 1/20 0.32
PIM1 P11309 1/20 0.32
PRKACA P17612 1/20 0.32
FLT3 P36888 1/20 0.32
CSNK1A1 P48729 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2917456 0.91 CDK2 (0.35) TTKCDK2EGFRCCNA2EPHB4
SCHEMBL2918733 0.87 IGF1R (0.41) TTKCDK2PDGFRBPDGFRAMETAP2
SCHEMBL2920925 0.85 CDC7 (0.46) CDK2EGFRSYKPDGFRBPDGFRA
SCHEMBL13175361 0.84 TNIK (0.35) TTKCDK2SYKCDK7CDK9
SCHEMBL2919558 0.81 CDC7 (0.40) SYKPDGFRBPDGFRACDC7IDO1
SCHEMBL2922109 0.81 ALK (0.34) TTKCDK2EGFRCCNA2PDGFRB
SCHEMBL2919831 0.80 IGF1R (0.43) CDK2SYKPDGFRBPDGFRAJAK3
SCHEMBL2921534 0.79 SYK (0.41) EPHB4SYKIDO1TDO2JAK3
SCHEMBL2920288 0.77 PDGFRB (0.37) CDK2SYKPDGFRBPDGFRACDC7
SCHEMBL2917536 0.77 CDK1 (0.39) TTKCDK2SYKPDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
WO-2009084695-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE DSTYK, ABL1, EEF2K TTK 103/4885CDK2 15/4885EGFR 479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.